TY - JOUR
T1 - Final adult height of patients with childhood-onset systemic lupus erythematosus
T2 - A cross sectional analysis
AU - Heshin-Bekenstein, Merav
AU - Perl, Liat
AU - Hersh, Aimee O.
AU - von Scheven, Emily
AU - Yelin, Ed
AU - Trupin, Laura
AU - Yazdany, Jinoos
AU - Lawson, Erica F.
N1 - Publisher Copyright:
© 2018 The Author(s).
PY - 2018/4/23
Y1 - 2018/4/23
N2 - Background: To compare final height to mid-parental target height among adults with childhood-onset systemic lupus erythematosus (cSLE) versus adult-onset SLE (aSLE), and to evaluate the impact of age at SLE onset on final height. Methods: Data derived from the Lupus Outcomes Study, a longitudinal cohort of adults with SLE, was used for this cross-sectional analysis (N=728). Participants aged 18-63 years with complete height data were included (N =566) and were classified as cSLE if age at diagnosis was <18 years (N=72). The Tanner formula was used to calculate mid-parental target height. Multivariate linear regression was used to determine mean difference between final height and target height. Multivariate logistic regression was used to compare odds of substantially reduced final height, defined as >2 SD below target height. Separate analyses were conducted for females and males to account for differences in timing of the pubertal growth spurt for each sex. Results: Participants with cSLE were, on average, 2.4 cm shorter than their target height (95% CI -4, -0.7). The adjusted odds ratio (OR) for substantially reduced final height was 3.9 (95% CI +2.0, +7.2, p<0.001) as compared to participants with aSLE. Females diagnosed between 11 and 13 years were at greatest risk for substantially reduced final height, with adjusted OR of 11.2 (95% CI +3.4, +36.3) as compared to participants with aSLE (p<0.001). Conclusions: cSLE is associated with shorter-than-expected final height. Onset of SLE in the pubertal period, near the time of maximum linear growth, may have a particularly significant impact on final height.
AB - Background: To compare final height to mid-parental target height among adults with childhood-onset systemic lupus erythematosus (cSLE) versus adult-onset SLE (aSLE), and to evaluate the impact of age at SLE onset on final height. Methods: Data derived from the Lupus Outcomes Study, a longitudinal cohort of adults with SLE, was used for this cross-sectional analysis (N=728). Participants aged 18-63 years with complete height data were included (N =566) and were classified as cSLE if age at diagnosis was <18 years (N=72). The Tanner formula was used to calculate mid-parental target height. Multivariate linear regression was used to determine mean difference between final height and target height. Multivariate logistic regression was used to compare odds of substantially reduced final height, defined as >2 SD below target height. Separate analyses were conducted for females and males to account for differences in timing of the pubertal growth spurt for each sex. Results: Participants with cSLE were, on average, 2.4 cm shorter than their target height (95% CI -4, -0.7). The adjusted odds ratio (OR) for substantially reduced final height was 3.9 (95% CI +2.0, +7.2, p<0.001) as compared to participants with aSLE. Females diagnosed between 11 and 13 years were at greatest risk for substantially reduced final height, with adjusted OR of 11.2 (95% CI +3.4, +36.3) as compared to participants with aSLE (p<0.001). Conclusions: cSLE is associated with shorter-than-expected final height. Onset of SLE in the pubertal period, near the time of maximum linear growth, may have a particularly significant impact on final height.
KW - Adult-onset SLE
KW - Childhood-onset SLE
KW - Final adult height
KW - Growth hormone
KW - Mid-parental target height
KW - SLE
UR - http://www.scopus.com/inward/record.url?scp=85045743438&partnerID=8YFLogxK
U2 - 10.1186/s12969-018-0239-8
DO - 10.1186/s12969-018-0239-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29688869
AN - SCOPUS:85045743438
SN - 1546-0096
VL - 16
JO - Pediatric Rheumatology
JF - Pediatric Rheumatology
IS - 1
M1 - 30
ER -